Sitagliptin versus semaglutide in type 2 diabetes mellitus

Abstract

The case report documents the superiority of GLP-1RA therapy when compared to DPP-4inhibitors. Within a half-year therapy with semaglutide, the patient's HbA1clevels werereduced by 13 mmol/mol, and the patient's body weight was reduced by 7 kg.

The patient hasreached the target HbA1clevels, and tolerates the treatment from its beginning with no sideeffects.

Keywords

• dipeptidyl peptidase-4inhibitors
• glucagon-like peptide-1receptor agonists
• type 2 diabetes mellitus